Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
about
Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loopsStructure of a V3-containing HIV-1 gp120 coreQuaternary structures of HIV Env immunogen exhibit conformational vicissitudes and interface diminution elicited by ligand bindingSolution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state.Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2)Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer.Stoichiometry of antibody neutralization of human immunodeficiency virus type 1.Which Antibody Functions are Important for an HIV Vaccine?Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.Interaction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolateSequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.Determinants of neutralization resistance in the envelope glycoproteins of a simian-human immunodeficiency virus passaged in vivo.Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Differential CD4/CCR5 utilization, gp120 conformation, and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate.Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies.The role of the third beta strand in gp120 conformation and neutralization sensitivity of the HIV-1 primary isolate DH012Enhancement of HIV infection by cellulose sulfate.Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoproteinA single amino acid substitution in the C4 region in gp120 confers enhanced neutralization of HIV-1 by modulating CD4 binding sites and V3 loop.AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.Differential utilization of CD134 as a functional receptor by diverse strains of feline immunodeficiency virus.Adaptive mutations in a human immunodeficiency virus type 1 envelope protein with a truncated V3 loop restore function by improving interactions with CD4.Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibodyNeutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor.Infection of equine monocyte-derived macrophages with an attenuated equine infectious anemia virus (EIAV) strain induces a strong resistance to the infection by a virulent EIAV strain.Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.Adaptation of subtype a human immunodeficiency virus type 1 envelope to pig-tailed macaque cellsA tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein.Immunogenic Display of Purified Chemically Cross-Linked HIV-1 Spikes.Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination.
P2860
Q24645530-886AF76D-BBF8-48CB-80AA-2A26736866B5Q27678226-A846D841-EF1C-4425-91E0-A64CD4236D7FQ29619014-687B6751-B813-4E41-A703-23FDD8676CEBQ30499590-DC5BFB8C-0465-4BD4-B990-3E33ACA4E584Q30524225-6BD0CDF4-7097-4B16-9488-AFBA62753EEAQ31143293-C326ED90-5E02-4B7C-AD23-1F0AADC7D86EQ33426352-239FA297-A1BB-45F9-9900-BDEAE314555DQ33640139-DC00AF63-7DEF-402B-83CF-2C2E203E9587Q33717477-3F8AD387-5A25-44F5-B0BC-80145EE1B4ECQ33725702-8ED34221-59CA-4698-864E-0503B4F1FE5CQ33737656-6CB0FA76-8C50-4C04-AC63-1B1526055AE8Q33772637-182FD107-1C4A-4F95-B206-160DBE3C7DD6Q33780620-C53F1FA1-98AF-4E2D-B87E-6AEB77978338Q33788874-CA964E84-7386-4986-9D87-2E1BECA9FF19Q33794954-C105D48B-6C8C-45CE-AC6B-223949CC3C3AQ33797989-D3B7719E-81DE-43EB-AF27-3831B57F26D5Q33813212-485A4A89-B597-4F9F-8A3D-77E75BE0E389Q33821658-E54D30E8-E8BB-4A33-BD8F-FE644C0CF7A3Q33836042-CF1FCB8E-C673-4C16-9E0A-FA3BD7CD54BBQ33839485-066DA596-1FED-4029-8972-A2550F4D170EQ33851094-A7ECBBA3-558D-4B32-B29D-47C0BF6F10F3Q33851405-3C4A39D9-DE6B-481A-80C5-0B6F96001FEFQ33870236-C3CD80D8-77E3-40FA-8B8C-0491DBAADB80Q33953062-82D15917-A0B1-465C-8B7E-787A84B5E7F8Q34080823-299A5547-4476-4204-9823-F94ECE91EF6CQ34347265-CBD8CC98-3C2D-4317-A63C-49172C097D53Q34463861-21138E6B-5D7D-4292-B852-8AD21339B5C2Q34464133-5E94450A-9B2D-4734-8468-CB0B1891C94BQ34545719-A673CC8A-77BB-45D8-892C-504E97699560Q34610959-5DE398C8-B792-4266-AAA2-C08351F12372Q34630446-62C0C0A2-072D-45B2-832E-C2C877F5A7A4Q34756144-ECB9D30E-2994-4BE8-91F3-76851FF315FEQ34812619-3A7C08C5-2BF4-487A-85C9-ECD4D31CC5F2Q34998032-1B537F44-CC1B-4089-8A5F-805669A2E964Q35076897-E4674815-E4A1-4437-BEC2-97D9B9D80B1EQ35140318-1F7686B5-5E81-4406-83C1-21DF4B5615FCQ35745442-45B5AE21-BB47-4741-A282-EB4070AA4FE6Q35825546-22C9BDC3-CF3C-4518-AE19-2ACBF7A257BBQ35826509-7D39D698-2205-40AC-8528-FB71A2F9BBF9Q36172480-AFCF4204-C193-4BB2-BB24-BD6311FED86B
P2860
Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@en
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@nl
type
label
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@en
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@nl
prefLabel
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@en
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@nl
P2093
P2860
P1433
P1476
Determinants of human immunode ...... CD4 and monoclonal antibodies.
@en
P2093
C F Barbas
D R Burton
J Sodroski
N Sullivan
P W Parren
P2860
P304
P407
P577
1998-08-01T00:00:00Z